Osteosarcoma, while relatively rare in humans (about 1000 cases per year in the U.S.), represents a continuing challenge to oncologists. Current chemotherapy regimens have a 60-70% five year survival rate. Thus, there is a need for more effective, less toxic therapies. We have extensively characterized a mouse osteosarcoma model to test therapies that may be transferable to human osteosarcomas. In this application, we propose a “proof of principle” experiment to show that downregulating the CSF-1 receptor (highly upregulated in mouse and human osteosarcomas) by siRNA and small molecule inhibitor approaches will result in significant inhibition of osteosarcoma growth in vivo.
Lawrence A. Donehower, Ph.D., Baylor College of Medicine
Recipient of the: $25,000 research award